No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ILMN Illumina
- 121.160
- -5.910-4.65%
Close Apr 15 16:00 ET
- 120.420
- -0.740-0.61%
Pre 06:51 ET
19.30BMarket Cap-16506P/E (TTM)
128.280High120.970Low1.62MVolume128.280Open127.070Pre Close198.10MTurnover1.02%Turnover RatioLossP/E (Static)159.26MShares229.58052wk High3.36P/B19.24BFloat Cap89.00052wk Low--Dividend TTM158.76MShs Float555.770Historical High--Div YieldTTM5.75%Amplitude0.855Historical Low122.518Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Looking Into Illumina's Recent Short Interest
Illumina's (NYSE:ILMN) short percent of float has risen 5.16% since its last report. The company recently reported that it has 5.21 million shares sold short, which is 3.67% of all regular shares that
Stocks With the Least Price Swings, Most Attractive Option-sale Candidates - JPM
Express News | Illumina’s Planned Divestment of Grail Approved by the European Commission
Express News | Illumina: in Event of Capital Markets Transaction, Co Must Capitalize Grail With 2-1/2 Years of Funding, Which Is Estimated at About $1 Bln
Express News | Illumina: Continues to Explore Divesting Grail Through Either Trade Sale or Capital Markets Transaction
Leerink Partners Adjusts Illumina's Price Target to $155 From $170
Leerink Partners Adjusts Illumina's Price Target to $155 From $170.
Comments
ColumnsMissed out on Nvidia? These Alternatives Are Expected to See Growth: Goldman Sachs
The landscape of U.S. equities is abuzz with anticipation as artificial intelligence (AI) cements its place as a transformative force in the technology sector. In a recent analysis by $Goldman Sachs(GS.US$, optimism for AI integration remains robust, yet valuations steer clear of the vertiginous heights of previous market bubbles.
Goldman Sachs' insights reveal that market-implied long-term growth expectations hav...
Goldman Sachs' insights reveal that market-implied long-term growth expectations hav...
72
1
Illumina's declining share price indicates market disappointment with its growth. The company's unprofitability and low revenue growth are seen as risky. Poor performance over the past year suggests unresolved challenges, and long-term share price weakness could be a bad sign. However, contrarian investors might see potential for a turnaround.
$Illumina(ILMN.US$ What happened 🤔
Given the liabilities on Illumina's balance sheet, relative to cash, and the company's EBIT loss over the last year, the existence of any debt seems unwise. The lack of profitability and decreasing revenue indicate a risk-averse environment for investors.
Jim Cramer reviews the worst performers on the Nasdaq-100 in 2023
Jim Cramer on Thursday gave his take on the worst performers in the Nasdaq-100 in 2023.
$Moderna(MRNA.US$ : Cramer noted that this pharmaceutical giant was also one of the bottom stocks on the S&P 500 last year, suggesting it may still be suffering from a post-Covid hangover.
$Illumina(ILMN.US$: Cramer likened this diagnostic equipment manufacturer to Moderna, a company that saw success during the pandemic but has since "failed t...
$Moderna(MRNA.US$ : Cramer noted that this pharmaceutical giant was also one of the bottom stocks on the S&P 500 last year, suggesting it may still be suffering from a post-Covid hangover.
$Illumina(ILMN.US$: Cramer likened this diagnostic equipment manufacturer to Moderna, a company that saw success during the pandemic but has since "failed t...
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Chen Kiat : Very informative